Eric Wang, Ph.D.

Eric Wang's Research Focus

Cancer, Immune Disorders, Molecular Biology
Adaptive Immunity, Cancer Biology, Disease Therapies, Tumor Microenvironment, Cell Biology
Chemical Biology, Drug Discovery

Dysregulation of transcriptional circuits is a common hallmark of disease, and in particular is found in both tumor and host immune cells in cancer. Eric’s lab is focusing on developing and using chemical tools to modulate the activity of key transcriptional regulators of both tumor cells and host immune cells, with a long-term goal of identifying new therapeutic approaches.

Eric Wang's Bio

Eric has a broad background in chemical biology, with specific training and expertise in kinase inhibitors and targeted protein degradation, an emerging modality in which small molecules recruit E3 ligase complexes to target proteins to induce their ubiquitination and subsequent proteasomal degradation. He also has experience in pharmacological modulation of immune cells to improve anti-tumor immunity.
 
He received his Ph.D. from the University of California San Francisco and postdoctoral training at the Dana-Farber Cancer Institute.

 

Education and Training

2021: Postdoctoral Fellow, Dana-Farber Cancer Institute / Harvard Medical School
2009: Ph.D., University of California San Francisco, 2015 B.S., Duke University

 

Fellowship

Damon Runyon Cancer Research Foundation Fellowship


general accessory

Publications

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK

Cancer Discov 2018 Feb ;8(2):216-233

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.

Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES, Treon SP, Weinstock DM, Gray NS

Blood 2019 Feb 28 ;133(9):952-961

Acute pharmacological degradation of Helios destabilizes regulatory T cells.

Wang ES, Verano AL, Nowak RP, Yuan JC, Donovan KA, Eleuteri NA, Yue H, Ngo KH, Lizotte PH, Gokhale PC, Gray NS, Fischer ES

Nat Chem Biol 2021 Jun ;17(6):711-717

Show All Select Publications

A cross-sectional survey on the lung ultrasound training and practice of respiratory therapists in mainland China.

Liu K, Yao YL, Wang YX, Wei BL, Li LC, Wang QX, Ge HQ, Wang ES, Yang LM, Chen H, Yang YQ, Qin H, Zhai WJ, Yu SJ, Wang XT, Luo Z, Tu GW

BMC Pulm Med 2022 Nov 18 ;22(1):425

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.

Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, Ulrickson ML, Gorak E, Bhatia S, Budak-Alpdogan T, Mason JR, Garcia-Romero MT, Lopez-Santiago NC, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran JM, Fathi AT, Hall A, Jacoby MA, Lancet JE, Mannis GN, Stein AS, Mims AS, Rizzieri D, Olin RL, Perl AE, Schiller GJ, Shami PJ, Stone RM, Strickland S, Wieduwilt MJ, Daver NG, Ravandi F, Vasu S, Guzman ML, Roboz GJ, Khoury JD, Qazilbash MH, Aung P, Cuglievan B, Madanat YF, Kharfan-Dabaja MA, Pawlowska AB, Taylor J, Tallman MS, Dhakal P, Lane AA

Blood 2022 Nov 18 ;

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE

Lancet Haematol 2022 Nov 9 ;

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients.

Sorror ML, Gooley TA, Storer BE, Gerds AT, Sekeres MA, Medeiros BC, Wang ES, Shami PJ, Adekola KUA, Luger SM, Baer MR, Rizzieri DA, Wildes T, Koprivnikar J, Smith J, Garrison M, Kojouri K, Schuler TA, Leisenring WM, Onstad L, Becker PS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey E

Blood 2022 Oct 19 ;

Acute pharmacological degradation of ERK5 does not inhibit cellular immune response or proliferation.

You I, Donovan KA, Krupnick NM, Boghossian AS, Rees MG, Ronan MM, Roth JA, Fischer ES, Wang ES, Gray NS

Cell Chem Biol 2022 Nov 17 ;29(11):1630-1638.e7

Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios.

Verano AL, You I, Donovan KA, Mageed N, Yue H, Nowak RP, Fischer ES, Wang ES, Gray NS

ACS Chem Biol 2022 Sep 16 ;17(9):2404-2410

Show All Publications